1ST Biotherapeutics and SK Biopharma License Parkinson’s Drug
Yongin, South Korea, September 17, 2026 1ST Biotherapeutics, Inc. (1STBIO) and SK Biopharmaceuticals Co., Ltd. (SKBP) have announced an...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Yongin, South Korea, September 17, 2026 1ST Biotherapeutics, Inc. (1STBIO) and SK Biopharmaceuticals Co., Ltd. (SKBP) have announced an...
NEW HAVEN, Conn. and SEOUL, South Korea, Aug. 26, 2026 Biohaven Ltd. and SK Biopharmaceuticals announced a strategic global...
BOSTON, MA and SEOUL, South Korea, June 22 2026 Insilico Medicine and SK Biopharmaceuticals have announced a landmark artificial...
